CXCR4 and acute myeloid leukemia: Our protein-only nanoparticle exploits a targeted drug delivery strategy that uses a CXCR4 ligand, named T22, to interact specifically with this receptor to trigger its internalization by endocytosis in target AML cells, an event confirmed by endosomal formation followed by subsequent endosomal escape [20,22].